Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment
Company Announcements

Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment

Alpha Tau Medical Ltd (DRTS) has released an update.

Alpha Tau Medical Ltd., a pioneer in alpha-radiation cancer therapy, has successfully treated its first patient with recurrent lung cancer using its breakthrough Alpha DaRT technology at Hadassah Medical Center in Jerusalem. The clinical trial, which allows for concurrent chemotherapy or immunotherapy, aims to assess the safety, feasibility, and efficacy of Alpha DaRT in treating tumors in the chest area. This development could potentially offer hope to a global patient population with limited treatment options for lung cancer, the leading cause of cancer-related deaths worldwide.

For further insights into DRTS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAlpha Tau Medical to Hold Annual Shareholder Meeting
TipRanks Auto-Generated NewsdeskAlpha Tau Joins FDA Program to Advance Cancer Therapy
TheFlyAlpha Tau announces acceptance into FDA’s TPLC TAP Pilot
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App